<?xml version="1.0" encoding="UTF-8"?><ns2:edgarSubmission xmlns:com="http://www.sec.gov/edgar/common" xmlns:ns2="http://www.sec.gov/edgar/ownership">
    <ns2:headerData>
        <ns2:submissionType>144</ns2:submissionType>
        <ns2:filerInfo>
            <ns2:filer>
                <ns2:filerCredentials>
                    <ns2:cik>0001601607</ns2:cik>
                    <ns2:ccc>XXXXXXXX</ns2:ccc>
                </ns2:filerCredentials>
            </ns2:filer>
            <ns2:liveTestFlag>LIVE</ns2:liveTestFlag>



        </ns2:filerInfo>
    </ns2:headerData>
    <ns2:formData>
        <ns2:issuerInfo>
            <ns2:issuerCik>0001069899</ns2:issuerCik>
            <ns2:issuerName>Phibro Animal Health Corporation</ns2:issuerName>
            <ns2:secFileNumber>001-36410</ns2:secFileNumber>
            <ns2:issuerAddress>
                <com:street1>Glenpointe Centre East, 3rd Floor</com:street1>
                <com:street2>300 Frank W. Burr Boulevard, Suite 21</com:street2>
                <com:city>Teaneck</com:city>
                <com:stateOrCountry>NJ</com:stateOrCountry>
                <com:zipCode>07666</com:zipCode>
            </ns2:issuerAddress>
            <ns2:issuerContactPhone>1-201-329-7300</ns2:issuerContactPhone>
            <ns2:nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>BFI Co., LLC</ns2:nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
            <ns2:relationshipsToIssuer>
                <ns2:relationshipToIssuer>10% Stockholder</ns2:relationshipToIssuer>
            </ns2:relationshipsToIssuer>
        </ns2:issuerInfo>
        <ns2:securitiesInformation>
            <ns2:securitiesClassTitle>Class A Common Share</ns2:securitiesClassTitle>
            <ns2:brokerOrMarketmakerDetails>
                <ns2:name>Goldman Sachs &amp; Co. LLC</ns2:name>
                <ns2:address>
                    <com:street1>200 West Street</com:street1>
                    <com:city>New York</com:city>
                    <com:stateOrCountry>NY</com:stateOrCountry>
                    <com:zipCode>10282</com:zipCode>
                </ns2:address>
            </ns2:brokerOrMarketmakerDetails>
            <ns2:noOfUnitsSold>257400</ns2:noOfUnitsSold>
            <ns2:aggregateMarketValue>4450446</ns2:aggregateMarketValue>
            <ns2:noOfUnitsOutstanding>20337574</ns2:noOfUnitsOutstanding>
            <ns2:approxSaleDate>08/13/2024</ns2:approxSaleDate>
            <ns2:securitiesExchangeName>NASD</ns2:securitiesExchangeName>
        </ns2:securitiesInformation>
        <ns2:securitiesToBeSold>
            <ns2:securitiesClassTitle>Class A Common Stock</ns2:securitiesClassTitle>
            <ns2:acquiredDate>04/14/2014</ns2:acquiredDate>
            <ns2:natureOfAcquisitionTransaction>Private placement from issuer of securities</ns2:natureOfAcquisitionTransaction>
            <ns2:nameOfPersonfromWhomAcquired>Phibro Animal Health Corporation</ns2:nameOfPersonfromWhomAcquired>
            <ns2:isGiftTransaction>N</ns2:isGiftTransaction>
            <ns2:amountOfSecuritiesAcquired>257400</ns2:amountOfSecuritiesAcquired>
            <ns2:paymentDate>04/14/2014</ns2:paymentDate>
            <ns2:natureOfPayment>Exchange of Securities</ns2:natureOfPayment>
        </ns2:securitiesToBeSold>
        <ns2:nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</ns2:nothingToReportFlagOnSecuritiesSoldInPast3Months>
        <ns2:remarks>The sales of shares set forth herein are made in connection with a selling plan dated 2/12/2024 that is intended to comply with Rule 10b5-1(c). The representation below regarding the seller's knowledge of material information was true as of the date the selling plan was entered into.</ns2:remarks>
        <ns2:noticeSignature>
            <ns2:noticeDate>08/13/2024</ns2:noticeDate>
            <ns2:planAdoptionDates>
                <ns2:planAdoptionDate>02/12/2024</ns2:planAdoptionDate>
            </ns2:planAdoptionDates>
            <ns2:signature>Goldman Sachs &amp; Co. LLC on behalf of Jack Bendheim</ns2:signature>
        </ns2:noticeSignature>
    </ns2:formData>
</ns2:edgarSubmission>
[{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 4128}]
144
0001601607
XXXXXXXX
LIVE
0001069899
Phibro Animal Health Corporation
001-36410
Glenpointe Centre East, 3rd Floor
300 Frank W. Burr Boulevard, Suite 21
Teaneck
NJ
07666
1-201-329-7300
BFI Co., LLC
10% Stockholder
Class A Common Share
Goldman Sachs & Co. LLC
200 West Street
New York
NY
10282
257400
4450446
20337574
08/13/2024
NASD
Class A Common Stock
04/14/2014
Private placement from issuer of securities
Phibro Animal Health Corporation
N
257400
04/14/2014
Exchange of Securities
Y
The sales of shares set forth herein are made in connection with a selling plan dated 2/12/2024 that is intended to comply with Rule 10b5-1(c). The representation below regarding the seller's knowledge of material information was true as of the date the selling plan was entered into.
08/13/2024
02/12/2024
Goldman Sachs & Co. LLC on behalf of Jack Bendheim